Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers May 22, 2017
Pharmacy Choice - Pharmaceutical News - Biosimilars Market Access in Psoriasis 2017 - Physicians Hesitant to Use Biosimilars, But Understand that Payers May Hold Sway - Research and Markets - May 22, 2017

Pharmacy News Article

 5/18/17 - Biosimilars Market Access in Psoriasis 2017 - Physicians Hesitant to Use Biosimilars, But Understand that Payers May Hold Sway - Research and Markets

DUBLIN, May 18, 2017 /PRNewswire/

Dublin - Research and Markets has announced the addition of the "Biosimilars Market Access in Psoriasis" report to their offering.

Research and Markets Logo

Tumor necrosis factor (TNF)-alpha inhibitors Enbrel, Humira, and Remicade have long held dominant positions in the psoriasis market; however, these market leaders face patent expirations and consequent biosimilar launches.

Payers are eager to leverage these changes in the competitive landscape and enact pro-biosimilar access measures, resulting in downward pricing pressures and/or continuing market erosion for first-generation TNF-alpha inhibitors. This rate of erosion may initially be gradual, as neither physicians nor payers are likely to advocate patient switching.

Key Topics Covered:

1. Executive Summary

  • Insights and strategic recommendations
  • Inflectra carries biosimilar labeling designation, but is not interchangeable
  • Physicians hesitant to use biosimilars, but understand that payers may hold sway
  • Bibliography

2. Five Major EU Markets

  • Insights and strategic recommendations
  • Uptake of biosimilar TNF-alpha inhibitors varies across EU markets as the EMA does not determine interchangeability
  • Most physicians and payers consider biosimilars to be interchangeable, and an opportunity to reduce costs, but worries around indication extrapolation remain
  • Payers use biosimilars to pressure originators on pricing
  • Hospitals continue to procure both biosimilars and originators; dynamic pricing environment observed
  • Biosimilars will be used as price benchmarks for pipeline agents
  • Payers are unlikely to implement strong incentives to drive uptake of biosimilar infliximab due to limited use of the drug
  • Bibliography

3. Methodology

  • Primary research

For more information about this report visit http://www.researchandmarkets.com/research/dr3pv9/biosimilars

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/biosimilars-market-access-in-psoriasis-2017-physicians-hesitant-to-use-biosimilars-but-understand-that-payers-may-hold-sway-research-and-markets-300460233.html

SOURCE Research and Markets




Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

LIVE ONLINE CE

Last Chance
May 22: Anticoagulants: The Rapidly Changing Landscape
May 24: Update on the Treatment for Major Depressive Disorder
May 25: Acne Vulgaris: Comprehensive Pharmaceutical Care
May 26: Dispensing Controlled Substances in Today’s Pharmacy
May 30: The American Geriatric Society Beers Criteria: Implications for Pharmacy Practice
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.



Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415